Document Detail


Relationship of circulating matrix biomarkers to myocardial matrix metabolism in advanced heart failure.
MedLine Citation:
PMID:  23143794     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
AIMS: Interstitial fibrosis is a key component of myocardial remodelling in heart failure (HF). Many studies have measured peripheral blood levels of procollagens and matrix metalloproteinases (MMPs), as a surrogate for myocardial matrix metabolism, particularly to evaluate the effect of interventions and their prognostic relevance. However, the relationship between peripheral biomarker levels and actual cardiac turnover in HF is not known. We aimed to determine whether peripheral levels of relevant biomarkers reflect cardiac release in patients with advanced HF. METHODS AND RESULTS: We determined whether the failing human heart releases collagen precursors [procollagen I N-terminal peptide (PINP) and procollagen III N-terminal peptide (PIIINP)], or key matrix metalloproteinases (MMP9) and MMP inhibitors [tissue inhibitor of metalloproteinase 1 (TIMP1)] by performing transcardiac blood sampling in healthy controls (n = 9) and in patients with advanced HF (n = 18, left ventricular ejection fraction 22 ± 2%). HF patients had higher arterial levels of PIIINP compared with controls (7.0 ± 0.7 vs. 4.0 ± 0.2 µg/L, P < 0.001). PIIINP was closely correlated with the pulmonary capillary wedge pressure (r = 0.54, P = 0.01) and the estimated glomerular filtration rate (r = -0.50, P = 0.01). Transcardiac blood sampling demonstrated that there was no net release of either PINP or PIIINP in controls or HF patients. The transcardiac MMP9 gradient was significantly lower in HF patients (P < 0.05), and was negatively correlated with left ventricular mass (r = -0.51, P = 0.01). CONCLUSIONS: Our study shows that the concentration of circulating levels of PINP, PIIINP, MMP9, and TIMP1 do not accurately reflect cardiac turnover. This study highlights the importance of performing transcardiac blood sampling to validate the utility of emerging cardiac biomarkers.
Authors:
David M Kaye; Ouda Khammy; Justin Mariani; Micha T Maeder
Related Documents :
24893874 - Impact of coronary collateral circulation and severity of coronary artery disease in th...
19395954 - Randomized trials of clinical networks in the management of st-elevation mi: can they b...
23337094 - Cardiac function in congenital adrenal hyperplasia: a pattern of reversible cardiomyop...
24371474 - New echocardiographic tehniques in pulmonary arterial hypertension vs. right heart cath...
24893874 - Impact of coronary collateral circulation and severity of coronary artery disease in th...
345984 - Acute neurological complications after liver transplantation with particular reference ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-9
Journal Detail:
Title:  European journal of heart failure     Volume:  -     ISSN:  1879-0844     ISO Abbreviation:  Eur. J. Heart Fail.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100887595     Medline TA:  Eur J Heart Fail     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Heart Failure Research Group, Baker IDI Heart and Diabetes Institute, Melbourne, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Critical role of fractalkine (CX3CL1) in cigarette smoke-induced mononuclear cell adhesion to the ar...
Next Document:  Heart failure determines the myocardial inflammatory response to injury.